Recent

% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • rman707 rman707 Mar 15, 2011 3:36 PM Flag

    Looks like "Still" had it right...

    Isn't this release referring to the European tests whereas the previous announcement was the USA test data; or have I missed something?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Ah, nope. You haven't missed anything.
      And, ah, yep. You're exactly correct the way you stated it.

      Today was about COMFORT-II, which was es-US PIII testing of Ruxolitinib; and back in December was about COMFORT-I, which was US PIII testing of Ruxolitinib. All of that lovely testing is now SUCCESSFULLY completed and in da' bag!

      Novartis does indeed own the ex-US rights to Ruxolitinib, and they may indeed have been conducting the COMFORT-II trial, but all of that is part of the agreement of the Incyte-Novartis worldwide collaboration and license agreement.
      And Incyte's name is still (most definitely) a part of that agreement, which makes today's news equally as relevant to INCY as to Novartis.

 
INCY
81.04+0.94(+1.17%)Aug 26 4:00 PMEDT